Full-Time

Executive Medical Director

Drug Safety

Confirmed live in the last 24 hours

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech startup developing innovative medicines

Compensation Overview

$300k - $327.8k/yr

+ Bonus + Equity Compensation

Expert

New York, NY, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Risk Management
Google Cloud Platform
Requirements
  • MD or DO with 10+ years of relevant experience
  • Must have US medical board certification
  • Highly-developed scientific and analytical knowledge base and an excellent understanding of good pharmacovigilance practices and current regulations within drug safety
  • Working knowledge of validated drug safety databases (preferably ARGUS) and MedDRA
  • Thorough understanding of U.S. pharmacovigilance regulations, GCP and International Conference on Harmonization (ICH) guidelines
  • Extensive experience in authoring of all types of aggregate safety reports including setting a strategy to address potential safety issues
  • Extensive experience in partnering with vendors to achieve results
  • Skilled at negotiating with business partners or managing and influencing senior level leaders regarding matters of significance to the organization
  • Ability to think strategically at the executive level, implement change, incorporate innovation, and implement strategies throughout all levels of the organization
  • Ability to build and sustain trusted relationships both internally and externally
Responsibilities
  • Provide oversight on all safety aspects of documents: clinical studies protocols, clinical study reports, IB, Labels (development and maintenance of the company core safety information) and SUSARS
  • Represent safety in communications with health authorities such as the FDA
  • Assess safety signals and trends and proactively manage any potential safety issues
  • Formulate response strategies and author responses for health authority requests
  • Accountable for medical evaluation/interpretation of aggregate safety data including signal detection and evaluation, and ad hoc safety assessments
  • Perform medical review of serious adverse events from Eikon clinical trials
  • Provide support for safety sections of clinical documents, including the review and approval of the safety portion of protocols, annual reports (DSUR), final study reports, IB and other documents as needed
  • Lead development of Risk Management Plans, implementation, and evaluation of their effectiveness
  • Ensure safety issues are communicated to the appropriate stakeholders in a timely fashion
  • Ensure Medical Safety activities are performed in compliance with all applicable regulations and company standards
  • Maintain knowledge of global regulatory authority regulations including FDA and EMA
  • Contribute to the training, leadership, and continuing education of department staff

Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking (SMT) platform to visualize protein motion in living cells, combined with artificial intelligence and automation for precise analysis of molecular interactions. Their diverse team integrates science and engineering to create therapies aimed at improving the lives of patients with serious diseases. Eikon's goal is to leverage advanced technologies to develop effective treatments for those in need.

Company Size

201-500

Company Stage

Series D

Total Funding

$1.1B

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon raised $350.7 million in Series D funding, boosting clinical-stage programs.
  • The company is advancing Phase 3 cancer treatments, including melanoma immunotherapy.
  • Strong investor confidence is evident with backing from Lux Capital and Soros Capital.

What critics are saying

  • Intellectual property disputes may arise over single-molecule tracking technology.
  • High valuation could attract regulatory scrutiny and financial compliance issues.
  • Significant real estate investments pose financial risks if growth projections falter.

What makes Eikon Therapeutics unique

  • Eikon uses proprietary single-molecule tracking for real-time protein movement analysis.
  • The company integrates AI and advanced automation in drug discovery processes.
  • Eikon's diverse team combines expertise in biology, engineering, and chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

6%
BioSpace
Mar 14th, 2025
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies.

Chronicles Magazine
Mar 3rd, 2025
Family office investors demonstrate appetite for innovation and diversity

Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.

Business Wire
Feb 27th, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a

Stat News
Feb 26th, 2025
Eikon Therapeutics raises $350 million

Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.

BioWorld
Feb 26th, 2025
Eikon raises $350.7M in Series D

Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.